UPC CFI 503/2024
Sep 2, 2024·EP2493466 · NOVEL ANTITUMORAL USE OF CABAZITAXEL
- Case details
- StatusCase Closed (Patent revoked)ActionCounterclaim for revocationCategoryCounterclaim for revocation
- Parties
- Claimants
- Zentiva, k.s.Operating co.
- Zentiva Pharma GmbHOperating co.
- Zentiva FranceOperating co.
Representatives- Anja Lunze
Respondents- Sanofi Mature IPOperating co.
Representatives- Agathe Michel-De Cazotte-Carpmaels & Ransford
- Division
- Munich LD
- Technology
- ChemistryPharmaceuticals
- Language
- English
- First decided
- Dec 12, 2025
- EPO Opposition
- Glenmark Pharmaceuticals Europe Ltd2021-03-10
- Accord Healthcare LtdAdmissible2021-03-10
- Teva Pharmaceutical Industries Ltd.Admissible2021-03-10
- EVER Valinject GmbHWithdrawn2021-03-12
- Zentiva k.s.Admissible2021-03-12
- medac Gesellschaft für klinische Spezialpräparate mbHWithdrawn2021-03-22
- Fresenius Kabi Deutschland GmbHAdmissible2021-03-23
- Dr. Reddy's Laboratories Ltd.Admissible2021-03-31
- Betapharm Arzneimittel GmbHAdmissible2021-03-31
- Generics (U.K.) LimitedAdmissible2021-06-08
- Vossius & Partner Patentanwälte Rechtsanwälte mbBAdmissible2021-12-03
- STADA Arzneimittel AGAdmissible2021-12-09
- Maiwald GmbHAdmissible2021-12-10
- Accord Healthcare S.L.U.2024-08-30
| Patent revoked | Median days to first decision | |
|---|---|---|
| All UPC | 37% (34/91) | 124 |
| Munich LD | Locked | Locked |
| Judge Matthias Zigann | Locked | Locked |
| Judge Alima Zana | Locked | Locked |
| Judge Tobias Pichlmaier | Locked | Locked |
At the UPC: Zentiva Group (15 cases)·Sanofi Group (33 cases)
This dispute contains 7 other proceedings
UPC CoA 24/2026·UPC CoA 27/2026·UPC CFI 98/2026·UPC CFI 99/2026·UPC CFI 148/2024 and 2 more
11 other defendants litigating the same or a related patent
UPC CoA 22/2026·UPC CoA 23/2026·UPC CoA 25/2026·UPC CoA 26/2026·UPC CFI 496/2024 and 6 more
- 2025-12-12Infringement ActionPublic
Summary: The Munich Local Division issued a rectification order under Rule 353 RoP correcting factual errors in a prior decision in the Sanofi v. Stada/Dr Reddy/Zentiva proceedings, including corrections regarding marketing authorisation holders and expert witness attribution.
Show the legal issues (1)
- Rectification of decisions Rule 353 RoP
- 2025-12-12Infringement ActionPublic
Summary: The Munich Local Division found patent EP 2 493 466 (relating to cabazitaxel pharmaceutical formulations) invalid for lack of inventive step in infringement proceedings brought by Sanofi against STADA, Dr. Reddy's and Zentiva entities, dismissing the infringement claims.
Show the legal issues (4)
- Inventive step (cabazitaxel formulation)
- Infringement
- Pharmaceutical patent
- Counterclaim for revocation
| Document title | Date | Public |
|---|---|---|
| Note | 2026-03-11 | Not public |
| Note | 2026-02-06 | Not public |
| Receipt | 2026-02-04 | Not public |
| Cover sheet | 2026-02-04 | Not public |
| Application document Claimant | 2026-02-04 | Not public |
| Receipt | 2026-01-12 | Not public |
| Cover sheet | 2026-01-12 | Not public |
| Exhibit document Applicant | 2026-01-12 | Not public |
| Exhibit document Applicant | 2026-01-12 | Not public |
| Exhibit document Applicant | 2026-01-12 | Not public |